Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Psychopharmacology (Berl). 2013 Oct 31;231(5):939–948. doi: 10.1007/s00213-013-3316-1

TABLE 1.

BASELINE PATIENT CHARACTERISTICS BY TREATMENT GROUP

DEMOGRAPHICS SERTRALINE (n = 17) PLACEBO (n = 19) STATISTIC
Age, years 29.6 (4.0) 31.7 (3.7) t(34)=−1.6, p=0.11
Race; n (%) FET p=1.0
Caucasian 16 (94%) 18 (95%)
Hispanic 1 (6%) 1 (5%)
Marital Status; n (%) FET p=0.65
Never Married 3 (17.7%) 1 (5.3%)
Married 13 (76.5%) 17 (89.5%)
Divorced 1 (6%) 1 (5.3%)
Education, years 14.4 (2.0) 14.0 (1.2) t(33)=0.75, p=0.46
Parity 1.9 (0.9) 1.9 (0.9) t(34)=0.15, p=0.88
Breastfeeding; n (%) 6 (35.3%) 5 (26.3%) χ2(1)=0.56, p=0.56
Onset of illness, weeks postpartum 3.9 (4.9) 2.5 (3.0) t(34)=1.1, p=0.30
Duration of illness, weeks 15.5 (13.6) 13.5 (12.3) t(34)=0.47, p=0.64
Clinic presentation, weeks postpartum 19.4 (12.0) 15.4 (12.2) t(34)=1.01, p=0.32
BEHAVIORAL SCALES SERTRALINE (n = 17) PLACEBO (n = 19) STATISTIC
Hamilton Depression 20.6 (2.8) 23.2 (3.9) t(34)= −2.26, p=0.03
Hamilton Anxiety 21.3 (6.3) 24.5 (5.8) t(27)= −1.43, p=0.16
Edinburgh Postnatal Depression 18.8 (2.6) 20.8 (5.7) t(26.2)=−1.44, p=0.16

Legend: Subject characteristics are listed as mean and standard deviations unless otherwise indicated. FET=Fisher’s exact test.